Infectious Disease | Technology Transfer

Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain

Read more about Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain

Summary:

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners to develop therapeutic cell populations arising out of these technologies. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of one or more therapies to treat various oncologies.

Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron

Read more about Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron

Summary:

The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections.

An Anti-Viral Polypeptide: Griffithsin

Read more about An Anti-Viral Polypeptide: Griffithsin

Summary:

Researchers at the NCI seek licensing and/or co-development research collaborations for anti-viral Griffithsin (GRFT) proteins.

Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19

Read more about Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19

Summary:

The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.

T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy

Read more about T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy

Summary:

The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.

Immunogens for Use in a High Efficacy HIV Vaccine

Read more about Immunogens for Use in a High Efficacy HIV Vaccine

Summary:

The Vaccine Branch is seeking statements of capability or interest from parties interested in licensing V1-deleted immunogens to further develop, evaluate, or commercialize an improved HIV vaccine.

Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection

Read more about Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection

Summary:

The NCI seeks co-development partners or licensees to further develop the novel ExoVII inhibitor(s) as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial strains.

Automated Digital Pathology Device for High-Throughput Demand

Read more about Automated Digital Pathology Device for High-Throughput Demand

Summary:

The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.

HIV-1 IN Mutant in a Single Round Vector

Read more about HIV-1 IN Mutant in a Single Round Vector

Summary:

The Retroviral Replication Laboratory of the National Cancer Institute actively seeks parties interested in non-exclusive licensing a collection of single-round vectors containing mutations in HIV-1 IN or RT.

Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use

Read more about Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use

Description of Technology:

This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003). Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.

Subscribe to Infectious Disease

Main Menu

Partnerships

Royalties

Reports

Resources

Policies & Regulations

About Us

Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain

Summary:

Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron

Summary:

An Anti-Viral Polypeptide: Griffithsin

Summary:

Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19

Summary:

T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy

Summary:

Immunogens for Use in a High Efficacy HIV Vaccine

Summary:

Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection

Summary:

Automated Digital Pathology Device for High-Throughput Demand

Summary:

HIV-1 IN Mutant in a Single Round Vector

Summary:

Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use

Description of Technology: